• Home
  • Products
  • About
  • Contact

expanded access program with maat013 in steroid refractory

Current Location : Home > expanded access program with maat013 in steroid refractory

  • Xenikos presents promising new data from expanded access

    Nijmegen the Netherlands December 9 2019The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in

    Get Price
  • Results from an Expanded Access Program of Anti-CD3/CD7

    Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard®) for the Treatment of Steroid-Refractory Acute Gvhd

    Get Price
  • Experimental Pharmaceuticals for Steroid-Refractory Acute

    Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. Abstract Acute GVHD (aGVHD) is a significant complication after allogeneic hematopoietic cell transplantation (HCT) occurring in up to 70 of HCT recipients. Steroid-refractory aGVHD represents a subset of patients failing initial therapy and is particularly

    Get Price
  • FDA Sets Review Date for Remestemcel-L for Steroid

    Jul 21 2020 · Kurtzberg J Prockop S Chaudhury S et al. Study 275 updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children.

    Get Price
  • MaaT Pharma to Provide Clinical Data for Lead Microbiome

    Mar 11 2021 · In addition to the early access program MaaT Pharma investigated its lead candidate MaaT013 in a multi-center single-arm open-label Phase 2

    Get Price
  • MaaT Pharma Announces Positive Data for Its Lead

    Aug 31 2020 · In the presented evaluation eleven patients with steroid-dependent (n=3) or steroid-refractory (n=8) intestinal aGVHD following allogeneic hematopoietic stem cell transplantation received at least one and up to three doses of MaaT013 as part of a compassionate program. Most patients (n=10) had developed GI-predominant aGVHD.

    Get Price
  • Xenikos presents promising new data from expanded access

    "More effective therapies for steroid-refractory acute graft-versus-host disease are urgently needed " said Dr. Van der Velden. "The results of the Phase 1/2 clinical trial and now in the expanded access program show highly promising response rates including complete remission and overall survival rates that are substantially

    Get Price
  • MaaT Pharma to Provide Clinical Data for Lead Microbiome

    Mar 11 2021 · In addition to the early access program MaaT Pharma investigated its lead candidate MaaT013 in a multi-center single-arm open-label Phase 2 clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant steroid-refractory acute GvHD (GI SR-aGvHD) patients (NCT).

    Get Price
  • Xenikos Presents Promising New Data from Expanded Access

    Dec 09 2019 · The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation.

    Get Price
  • Xenikos Presents Promising New Data from Expanded Access

    Dec 09 2019 · The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation.

    Get Price
  • Expanded Access Program With MaaT013 in Steroid-refractory

    Expanded Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it

    Get Price
  • MaaT Pharma to Provide Data Update for Lead Microbiome

    Nov 26 2020 · MaaT Pharma announced today that updated results from its compassionate use program for lead microbiome therapeutic MaaT013 will be reported in an oral presentation at the virtual 62nd American Society of Hematology (ASH) Annual Meeting held from December 5 -8 2020. The results include data from 29 patients with gastrointestinal acute Graft-versus-Host-Disease (aGvHD)

    Get Price
  • Successful and Safe Treatment of Intestinal Graft-Versus

    Nov 05 2020 · Twenty-nine allo-HSCT recipients with steroid-dependent or SR intestinal GvHD (classical aGVHD n=22 late-onset aGVHD n=2 aGvHD with overlap syndrome n=5) were treated with MaaT013 biotherapeutic as part of a compassionate use/expanded access treatment program of the developer MaaT Pharma.

    Get Price
  • FDA Sets Review Date for Remestemcel-L for Steroid

    Jul 21 2020 · Kurtzberg J Prockop S Chaudhury S et al. Study 275 updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children.

    Get Price
  • Xenikos presents promising new data from expanded access

    Dec 09 2019 · Nijmegen the Netherlands December 9 2019The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem

    Get Price
  • MaaT Pharma Presents Positive Updated Results with its

    Dec 07 2020 · MaaT Pharma announced today positive updated clinical results from its lead full-ecosystem microbiome restoration biotherapeutic MaaT013 at the virtual 62nd American Society of Hematology (ASH

    Get Price
  • Study 275 Updated Expanded Access Program for Remestemcel

    May 01 2020 · Study 275 Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. Author links open overlay panel Joanne Kurtzberg 1 Susan Prockop 2 Sonali Chaudhury 3 Biljana Horn 4 Eneida Nemecek 5 Vinod Prasad 1 Prakash Satwani 6 Pierre Teira 7 Jack Hayes 8 Elizabeth Burke 8 for the MSB-275 Study

    Get Price
  • MaaT Pharma Announces Positive Topline Results from Phase

    Mar 17 2021 · The HERACLES trial data as well as the early access program results obtained in a larger and more diverse subpopulation of patients demonstrate the real-life benefit MaaT013

    Get Price
  • MaaT Pharma Presents Positive Updated Results with its

    MaaT Pharma announced today positive updated clinical results from its lead full-ecosystem microbiome restoration biotherapeutic MaaT013 at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. The data stems from a compassionate use/expanded access treatment program in France called Autorisation Temporaire d Utilisation Nominative (ATUn) using MaaT013 to treat patients

    Get Price
  • (PDF) Study 275 Updated Expanded Access Program for

    Study 275 Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) in Children February 2020 Biology of Blood and Marrow Transplantation

    Get Price
  • MaaT Pharma to Provide Clinical Data for Lead Microbiome

    Mar 11 2021 · In addition to the early access program MaaT Pharma investigated its lead candidate MaaT013 in a multi-center single-arm open-label Phase 2 clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in steroid-refractory gastrointestinal-predominant acute GvHD (SR-GI-aGvHD) patients (NCT).

    Get Price
  • Xenikos presents promising new data from expanded access

    "More effective therapies for steroid-refractory acute graft-versus-host disease are urgently needed " said Dr. Van der Velden. "The results of the Phase 1/2 clinical trial and now in the expanded access program show highly promising response rates including complete remission and overall survival rates that are substantially

    Get Price
  • Xenikos Presents Promising New Data from Expanded Access

    Dec 09 2019 · The Dutch company Xenikos B.V. which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation.

    Get Price
  • Study 275 Updated Expanded Access Program for Remestemcel

    Study 275 Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.

    Get Price
  • Successful and Safe Treatment of Intestinal Graft-Versus

    Nov 05 2020 · Twenty-nine allo-HSCT recipients with steroid-dependent or SR intestinal GvHD (classical aGVHD n=22 late-onset aGVHD n=2 aGvHD with overlap syndrome n=5) were treated with MaaT013 biotherapeutic as part of a compassionate use/expanded access treatment program of the developer MaaT Pharma.

    Get Price
  • MaaT Pharma Presents Positive Updated Results with its

    MaaT Pharma announced today positive updated clinical results from its lead full-ecosystem microbiome restoration biotherapeutic MaaT013 at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. The data stems from a compassionate use/expanded access treatment program in France called Autorisation Temporaire d Utilisation Nominative (ATUn) using MaaT013 to treat patients

    Get Price
  • MaaT Pharma to Provide Clinical Data for Lead Microbiome

    MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic MaaT013 will be reported in an oral presentation at the virtual 47th Annual Meeting

    Get Price
  • MaaT Pharma Announces Positive Topline Results from Phase

    The HERACLES trial data as well as the early access program results obtained in a larger and more diverse subpopulation of patients demonstrate the real-life benefit MaaT013 can provide to these

    Get Price
  • MaaT Pharma Presents Positive Updated Results with its

    Dec 07 2020 · The data stems from a compassionate use/expanded access treatment program in France called Autorisation Temporaire d Utilisation Nominative (ATUn) using MaaT013 to treat patients that developed acute Graft-versus-Host-Disease with GI involvement (GI aGvHD) following allogeneic hematopoietic cell transplantation (allo-HCT) and were refractory to multiple lines of treatments

    Get Price
  • Xenikos presents promising new data from expanded access

    Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting • MC Services corporate website. 5295.

    Get Price

Products News

  • lining refractory refractory lining material recommendation for cement
  • china refractory castable low cement refractory castablefire clay refractory castable
  • the basic metals industry is one of the world s largest
  • ceramic tech syllabus refractory ceramics free 30
  • tundish lining systems
  • silicon carbide suppliers exporters in pakistan
  • north american refractories company is the brand
  • refractory precast equipment ezg manufacturing
  • how to build a plastic bag digester the complete biogas
  • coke calcining refractory products high heat applicationprecast block

Product Center

  • Alumina Hollow Ball Bricks
  • Corundum Spinel Castable
  • High Alumina Refractory Cement
  • High Alumina Low Cement Castable
  • High Alumina Refractory Ramming Mass
  • Trough Refractory Castable
  • Magnesium Iron Spinel Brick
  • Mullite Brick
  • Zirconium Mullite Brick

Hot Products

  • Light Weight Silica Insulation Brick
  • Zirconia Hollow Sphere Brick
  • Corundum Refractory Castable
  • Heavy Alkali Resistant Castable
  • High Alumina Low Cement Castable
  • High Alumina Self Flowing Castable
  • Micro Expansion Refractory Plastic
  • Phosphate Refractory Mud
  • Magnesia Zircon Brick

Images Show

About Us

Rongsheng's main products are various types of unshaped refractory products, which are widely used in metallurgy, nonferrous metals, building materials, electric power, petrochemical and other industries.

Rongsheng pays attention to technological innovation and product research and development, and has established close cooperative relations with many universities and scientific research institutes.

Zhengzhou Rongsheng Company © Copyrights. Sitemap